Mutant Pharmaceuticals

Mutant is a precision oncology company founded by the veteran leadership team behind Loxo Oncology, including Josh Bilenker and Jeff Engelman. The company focuses on the discovery and development of highly selective small molecule therapies designed to target specific genetic drivers of cancer. By leveraging advanced structural biology and medicinal chemistry, Mutant aims to address previously undruggable targets for molecularly defined patient populations. The firm is backed by a significant $300 million Series A investment from prominent venture capital firms such as ARCH Venture Partners and GV. Headquartered in Easton, Maryland, Mutant is currently in the pre-clinical stage of development for its pipeline of oncology candidates.